PCOS is Now PMOS: Why Global Health Experts Changed the Name of the Common Hormonal Disorder
The official renaming of PCOS to PMOS ( Polycystic Metabolic Ovarian Syndrome ) marks a turning point in how one of the world's most common endocrine disorders is understood. For decades, the name ‘Polycystic Ovary Syndrome’ led many patients and even some practitioners to believe that the presence of ovarian cysts was the primary requirement for diagnosis. However, as medical science evolved, it became clear that many women with the syndrome never develop cysts, while the underlying metabolic dysfunction such as insulin resistance remains a constant threat.
The primary driver behind the move to PMOS is the need for clinical accuracy. "PCOS" was often a misnomer; the "cysts" seen on ultrasounds are actually underdeveloped follicles, not true cysts. More importantly, the old name ignored the systemic nature of the condition. By incorporating the word Metabolic, the new terminology forces a focus on the increased risks of Type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease that come with the syndrome.
In India, where an estimated one in five women suffers from the condition, the name change is expected to have a profound impact on early intervention. Indian women are genetically more predisposed to insulin resistance and "lean PCOS" (where weight is not an indicator). Experts believe that "PMOS" will encourage Indian doctors to look beyond ultrasound results and prioritize metabolic screenings, such as fasting insulin and glucose tolerance tests, leading to more accurate diagnoses in a population often hit hard by metabolic complications.
Why the Change Was Necessary
The primary driver behind the move to PMOS is the need for clinical accuracy. "PCOS" was often a misnomer; the "cysts" seen on ultrasounds are actually underdeveloped follicles, not true cysts. More importantly, the old name ignored the systemic nature of the condition. By incorporating the word Metabolic, the new terminology forces a focus on the increased risks of Type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease that come with the syndrome.
Impact on Women in India
In India, where an estimated one in five women suffers from the condition, the name change is expected to have a profound impact on early intervention. Indian women are genetically more predisposed to insulin resistance and "lean PCOS" (where weight is not an indicator). Experts believe that "PMOS" will encourage Indian doctors to look beyond ultrasound results and prioritize metabolic screenings, such as fasting insulin and glucose tolerance tests, leading to more accurate diagnoses in a population often hit hard by metabolic complications.
Next Story